GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal

GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash, adding 15 U.S. CMO sites, 21 cyclotrons and U.S. rights to the Phase III FAPI-74 PET radiotracer; closing is expected in the first half of 2027, subject to regulatory approvals. GEHC expects the deal to boost revenue growth, adjusted EBIT margin and adjusted EPS in its first full year of ownership, and its shares rose 2.3% at the close after the announcement.

Analysis

The strategic value is less the site count than control of a time-critical distribution network: denser local production can improve reliability and capture third-party manufacturing demand, while making GEHC a more consequential partner to PET-tracer developers. The counterweight is utilization. Cyclotron capacity is not automatically valuable if local scan volumes, reimbursement or tracer adoption lag; economics will depend on throughput, customer retention and the cost of operating a geographically dispersed network.

There is also a neutrality risk. SOFIE’s continued service to outside customers preserves the opportunity, but developers could reassess whether GEHC-owned capacity gives a competitor preferential access or insight. Any customer migration would undermine the assumed network value. For GEHC, FAPI-74 is meaningful option value, not yet a dependable earnings driver: Phase III results, regulatory progress and commercial uptake matter more than broad pipeline counts.

Near term, the announcement-driven move may be ahead of verifiable earnings impact: closing is distant, and first-full-year accretion is management’s forecast without disclosed utilization, purchase multiple or integration detail. Over 1–3 months, focus on deal terms, customer-retention signals and updated guidance; over 6–18 months, watch closing progress and evidence that capacity translates into profitable volume. The thesis weakens if approvals slip, customers leave, or management cannot demonstrate improving segment growth and margins. No peer-specific read-through is strong enough to justify a trade in OPK, GMED or WST.

Key Decisions for Investors

• GEHC: Treat the deal as strategically constructive but not a near-term earnings upgrade. Avoid chasing the announcement; consider a measured long only on weakness, contingent on confirming financing treatment and purchase economics.
• Set diligence alerts for acquired-network utilization, third-party customer retention, integration/capex needs, and whether GEHC revises Pharmaceutical Diagnostics growth or margin expectations. These are the proof points for the claimed accretion.
• Do not assign material value to FAPI-74 until Phase III and regulatory milestones de-risk it. Reassess after clinical data or a filing; failure or delay would remove a key strategic upside.
• Monitor competing radiopharmaceutical developers’ manufacturing arrangements and any signs of customer diversion. Evidence that SOFIE customers avoid GEHC ownership would challenge the network thesis; no immediate short is warranted without that evidence.